Clinical trial
A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia
NCT04881240 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study Evaluating Allogeneic Memory T Cells Engineered to Express Chimeric Antigen Receptors Specific for CD19 for the Treatment of Pediatric and Young Adult Patients ≤ 21 Years of Age With Relapsed or Refractory CD19-Positive Leukemia
- Lead sponsor
- St. Jude Children's Research Hospital
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 14, 2024
- Completion date
- July 1, 2028
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, in relapse, acute lymphoblastic leukemia, refractory, pediatric all